Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02345382 · ClinicalTrials.gov registry record · Phase 1
Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia
A Phase 1 study, sponsored by Bayer.
- Completed
- Registry status
- Phase 1
- Development phase
- 42
- Enrollment target
NCT02345382 is a Phase 1 study that has completed, run by Bayer. The registered enrollment target is 42 participants.
The verdict
NCT02345382, a Phase 1 study, has completed, sponsored by Bayer.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 42 participants
- Enrollment target
Study Summary
To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia
Interventions
- DRUG Atuveciclib, BAY1143572
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 42 participants |
| Start Date | 2015-02-19 |
| Est. Completion | 2017-07-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02345382
The ClinicalTrials.gov registry entry for NCT02345382 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 42 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bayer, which has 591 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Atuveciclib, BAY1143572 is the first listed.
NCT02345382 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02345382 about?
NCT02345382 is a clinical study titled "Phase I Dose Escalation of BAY1143572 in Subjects With Acute Leukemia". To determine the safety, tolerability, pharmacokinetics, maximum tolerated dose, and recommended Phase II dose of BAY1143572 in a once-daily or an intermittent dosing schedule in subjects with advanced acute leukemia
What is the current status of trial NCT02345382?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 42 participants. The study started on 2015-02-19. Estimated completion is 2017-07-30.
What interventions are being tested in trial NCT02345382?
The interventions under investigation include: Atuveciclib, BAY1143572 (DRUG).
Who is sponsoring clinical trial NCT02345382?
This trial is sponsored by Bayer, which has 591 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.